Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.

ABSTRACT:

Importance

There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.

Objective

To assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis.

Design, setting, and participants

Double-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.

Interventions

Patients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratif

SUBMITTER: Pose E 

PROVIDER: S-EPMC11800124 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature